Viracta Therapeutics, Inc. (VIRX) Reports In-Line Q3 EPS

Viracta Therapeutics, Inc. (NASDAQ: VIRX) reported Q3 EPS of ($0.27), in-line with the analyst estimate of ($0.27).

For earnings history and earnings-related data on Viracta Therapeutics, Inc. (VIRX) click here.

You May Also Be Interested In

• BlackBerry (BB) Tops Q1 EPS by 1c, Offers Guidance
• Evertz Technology (ET:CN) (EVTZF) PT Raised to Cdn$18 at BMO Capital
• Worthington Steel, Inc. (WS) Misses Q4 EPS by 3c